Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 13990.0
(-1.82%)
KRW 13990.0
(-1.82%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.78 Billion KRW | 62.74% |
| 2022 | -26.31 Billion KRW | -183.24% |
| 2021 | -9.28 Billion KRW | -109.69% |
| 2020 | -4.42 Billion KRW | -283.06% |
| 2019 | 2.41 Billion KRW | 64.83% |
| 2018 | 1.46 Billion KRW | -0.63% |
| 2017 | 1.47 Billion KRW | 121.22% |
| 2016 | -6.96 Billion KRW | -607.12% |
| 2015 | 1.37 Billion KRW | 533.01% |
| 2014 | 216.93 Million KRW | 102.6% |
| 2013 | -8.35 Billion KRW | -61.7% |
| 2012 | -5.16 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.22 Billion KRW | 134.72% |
| 2024 Q2 | -3.86 Billion KRW | -416.97% |
| 2023 Q3 | -2.01 Billion KRW | -1.92% |
| 2023 Q1 | -2.29 Billion KRW | 78.83% |
| 2023 FY | -9.8 Billion KRW | 62.74% |
| 2023 Q4 | -3.51 Billion KRW | -74.37% |
| 2023 Q2 | -1.97 Billion KRW | 13.85% |
| 2022 FY | -26.31 Billion KRW | -183.24% |
| 2022 Q4 | -10.84 Billion KRW | -49.07% |
| 2022 Q1 | -2.5 Billion KRW | 38.88% |
| 2022 Q2 | -5.68 Billion KRW | -127.4% |
| 2022 Q3 | -7.27 Billion KRW | -27.86% |
| 2021 Q1 | -1.92 Billion KRW | 50.84% |
| 2021 Q4 | -4.09 Billion KRW | -107.96% |
| 2021 FY | -9.28 Billion KRW | -109.69% |
| 2021 Q2 | -1.29 Billion KRW | 32.77% |
| 2021 Q3 | -1.96 Billion KRW | -51.71% |
| 2020 Q1 | 205.43 Million KRW | -76.62% |
| 2020 Q3 | -887.28 Million KRW | -598.22% |
| 2020 Q4 | -3.92 Billion KRW | -342.5% |
| 2020 FY | -4.42 Billion KRW | -283.06% |
| 2020 Q2 | 178.09 Million KRW | -13.31% |
| 2019 Q4 | 878.58 Million KRW | 405.9% |
| 2019 Q3 | 173.66 Million KRW | -72.99% |
| 2019 Q2 | 643.02 Million KRW | -11.26% |
| 2019 Q1 | 724.63 Million KRW | 1517.64% |
| 2019 FY | 2.41 Billion KRW | 64.83% |
| 2018 FY | 1.46 Billion KRW | -0.63% |
| 2018 Q3 | 491.11 Million KRW | -23.41% |
| 2018 Q2 | 641.18 Million KRW | 120.3% |
| 2018 Q1 | 291.04 Million KRW | -33.81% |
| 2018 Q4 | 44.79 Million KRW | -90.88% |
| 2017 Q3 | 928.01 Million KRW | 80.17% |
| 2017 FY | 1.47 Billion KRW | 121.22% |
| 2017 Q2 | 515.08 Million KRW | 222.9% |
| 2017 Q1 | -419.1 Million KRW | 92.68% |
| 2017 Q4 | 439.68 Million KRW | -52.62% |
| 2016 Q3 | -1.49 Billion KRW | -896.83% |
| 2016 Q4 | -5.72 Billion KRW | -283.36% |
| 2016 FY | -6.96 Billion KRW | -607.12% |
| 2016 Q1 | 403.59 Million KRW | 285.92% |
| 2016 Q2 | -149.81 Million KRW | -137.12% |
| 2015 Q3 | 825.62 Million KRW | 160.92% |
| 2015 Q1 | 430.9 Million KRW | 1497.16% |
| 2015 FY | 1.37 Billion KRW | 533.01% |
| 2015 Q4 | -217.08 Million KRW | -126.29% |
| 2015 Q2 | 316.43 Million KRW | -26.57% |
| 2014 Q3 | 905.86 Million KRW | 14772.25% |
| 2014 Q1 | -664.18 Million KRW | 77.64% |
| 2014 FY | 216.93 Million KRW | 102.6% |
| 2014 Q4 | -30.84 Million KRW | -103.4% |
| 2014 Q2 | 6.09 Million KRW | 100.92% |
| 2013 Q2 | -2.34 Billion KRW | -87.95% |
| 2013 Q4 | -2.97 Billion KRW | -66.27% |
| 2013 Q3 | -1.78 Billion KRW | 23.81% |
| 2013 FY | -8.35 Billion KRW | -61.7% |
| 2013 Q1 | -1.24 Billion KRW | -260.15% |
| 2012 Q4 | 779.07 Million KRW | 0.0% |
| 2012 FY | -5.16 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 9.55 Billion KRW | 202.357% |
| ST Pharm Co.,Ltd. | 31.03 Billion KRW | 131.529% |
| ABL Bio Inc. | -27.32 Million KRW | -35714.291% |
| Cellid, Co., Ltd. | -12.19 Billion KRW | 19.78% |